[Infections with hepatitis B virus in hemodialysis units of Wielkopolska].
OBJECTIVE
Epidemiological analysis of HBV infections in dialysis units of Wielkopolska.


METHODS
Studies were carried out in 19 dialysis units, in which patients were treated with intermittent hemodialysis (IHD). Data were collected from 18.04.2007 to 18.06.2007.


METHODS
There were 39 persons with HBsAg(+) among 1140 patients (3.42%). Positive results of HBcAb were shown in 114 from 349 examined patients with HBsAg(-) (32.7%). The group with HBsAg(+) consisted of 7 women (17.9%) and 32 men (82.1%). Documented duration of HBV infection was 9.7 +/- 6.0 years. Eight patients before detection of HBsAg(+) were vaccinated against hepatitis B; 21 patients (53.8%) underwent surgical interventions or invasive diagnostic procedures. Transfusions of blood or blood-related products were documented in 17 cases (43.6%). HBV infection in at least 32 patients (82.1%) was not connected with IHD treatment (p = 0.000). Four patients (10.3%) showed symptoms of acute hepatitis. Eleven patients (28.2%) with HBsAg(+) had renal transplantation. Patients with HBsAg(-) were vaccinated against hepatitis B. Vaccination was not effective (level of HBsAb < 10 IU/l) in 244 patients (22.2%).


CONCLUSIONS
HBV infection in patients with chronic kidney disease is most frequently detected before or due to initiation of IHD treatment. Over 20% IHD patients remains susceptible for HBV infection despite vaccination against hepatitis B.
Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych, Uniwersytet Medyczny im. K. Marcinkowskiego, Poznań. alicja_grzegorzewska@yahoo.com
Alicja E
AE
Grzegorzewska
Danuta
D
Kurzawska-Firlej
Andrzej
A
Swiderski
Maria
M
de Mezer-Dambek
Dorota
D
Frankiewicz
Danuta
D
Zaremba-Drobnik
Wojciech
W
Banachowicz
Ariana
A
Dumanowska-Zmuda
Włodzimierz
W
Ratajewski
Leszek
L
Niepolski
Robert
R
Krawczyk
Jacek
J
Sobolewski
Jan
J
Pulchny
Jacek
J
Molenda
Jan
J
Wojciechowski
Zenon
Z
Mikstacki
Jacek
J
Zachwieja
D000328:Adult; D000368:Aged; D015897:Comorbidity; D005260:Female; D006436:Hemodialysis Units, Hospital / Q000706:statistics & numerical data*; D006509:Hepatitis B / Q000175:diagnosis* / Q000453:epidemiology* / Q000517:prevention & control; D006511:Hepatitis B Antigens / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000628:therapy*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D006435:Renal Dialysis / Q000009:adverse effects / Q000706:statistics & numerical data*; D012189:Retrospective Studies
D006511:Hepatitis B Antigens; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines